{"id":"herpes-zoster-vaccine-live","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a weakened form of varicella-zoster virus that replicates in the body without causing disease, triggering both cellular and humoral immune responses. This boosts immunity against the virus, reducing the risk of herpes zoster reactivation in individuals with prior chickenpox infection and decreasing the severity of disease if breakthrough infection occurs.","oneSentence":"This live attenuated vaccine stimulates the immune system to recognize and respond to varicella-zoster virus, preventing herpes zoster (shingles) reactivation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:42.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults with prior varicella infection"}]},"trialDetails":[{"nctId":"NCT07485283","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2026-03","conditions":"Cardiovascular Disease, Dementia","enrollment":162000},{"nctId":"NCT07481604","phase":"PHASE2","title":"Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2026-04","conditions":"Herpes Zoster","enrollment":135},{"nctId":"NCT07473427","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-05-01","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07475000","phase":"PHASE3","title":"Second Dose of Varicella Vaccine in Healthy Children","status":"RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-01-28","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT07321808","phase":"","title":"Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2023-05-16","conditions":"Immunocompromised Patients","enrollment":300},{"nctId":"NCT07415252","phase":"PHASE3","title":"SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-06-05","conditions":"Varicella (Chickenpox)","enrollment":780},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07354659","phase":"PHASE2","title":"Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-01-10","conditions":"Herpes Zoster","enrollment":800},{"nctId":"NCT06932523","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-04-04","conditions":"Herpes Zoster (HZ)","enrollment":645},{"nctId":"NCT07311148","phase":"PHASE2","title":"A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-23","conditions":"Herpes Zoster (HZ), Shingles, VZV","enrollment":840},{"nctId":"NCT02723773","phase":"PHASE3","title":"A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":7539},{"nctId":"NCT04091451","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-09-17","conditions":"Herpes Zoster","enrollment":1430},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT05811754","phase":"","title":"Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-05-09","conditions":"Herpes Zoster","enrollment":2844},{"nctId":"NCT06890416","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-04","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":526},{"nctId":"NCT06569823","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over","status":"RECRUITING","sponsor":"Dynavax Technologies Corporation","startDate":"2024-06-17","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":764},{"nctId":"NCT06605625","phase":"","title":"Vaccine Responses in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-11-04","conditions":"Viral Vaccines","enrollment":250},{"nctId":"NCT07170059","phase":"","title":"Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-10-01","conditions":"Lung Cancer","enrollment":500},{"nctId":"NCT03604406","phase":"PHASE2","title":"The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2014-05-08","conditions":"Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT05701800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-01-23","conditions":"Herpes Zoster","enrollment":659},{"nctId":"NCT06409494","phase":"PHASE1","title":"Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"EuBiologics Co.,Ltd","startDate":"2024-07-15","conditions":"Varicella Zoster Virus Infection, Herpes Zoster","enrollment":72},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT05550194","phase":"PHASE4","title":"VZV in the Enteric Nervous System: Pathogenesis and Consequences","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-03-27","conditions":"Achalasia","enrollment":40},{"nctId":"NCT06961721","phase":"PHASE4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-05","conditions":"Prevention of Herpes Zoster","enrollment":600},{"nctId":"NCT03798691","phase":"PHASE4","title":"Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-05-28","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":33},{"nctId":"NCT06874842","phase":"PHASE1","title":"Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older","status":"RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-03-13","conditions":"Herpes Zoster (HZ)","enrollment":92},{"nctId":"NCT05966090","phase":"PHASE3","title":"A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-28","conditions":"Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections","enrollment":530},{"nctId":"NCT06891872","phase":"PHASE4","title":"Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2025-05","conditions":"Varicella (chickenpox), MMR Vaccine, DTaP Vaccine","enrollment":720},{"nctId":"NCT06581575","phase":"PHASE2","title":"A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2024-10-16","conditions":"Herpes Zoster (HZ), Infectious Diseases, Shingles","enrollment":467},{"nctId":"NCT06335849","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-03-27","conditions":"Herpes Zoster","enrollment":48},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT06801509","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-02-15","conditions":"Herpes Zoster","enrollment":540},{"nctId":"NCT05095701","phase":"PHASE4","title":"An Immunity Persistence Study of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-12-18","conditions":"Varicella","enrollment":703},{"nctId":"NCT06314724","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-02-29","conditions":"Varicella","enrollment":642},{"nctId":"NCT06484686","phase":"PHASE4","title":"An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-16","conditions":"Varicella","enrollment":414},{"nctId":"NCT04869982","phase":"PHASE4","title":"Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-14","conditions":"Herpes Zoster","enrollment":6138},{"nctId":"NCT06763783","phase":"PHASE4","title":"Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Region Skane","startDate":"2024-12-17","conditions":"Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis","enrollment":240},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT06654700","phase":"PHASE3","title":"Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-12-09","conditions":"Herpes Zoster","enrollment":1200},{"nctId":"NCT05636436","phase":"PHASE1","title":"Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2022-12-07","conditions":"Herpes Zoster","enrollment":132},{"nctId":"NCT05856084","phase":"PHASE2","title":"Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-05-07","conditions":"Herpes Zoster","enrollment":924},{"nctId":"NCT06137755","phase":"PHASE1","title":"Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above","status":"RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2023-03-15","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":32},{"nctId":"NCT04169009","phase":"PHASE4","title":"Persistence of Protection by Shingrix","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-07-28","conditions":"Herpes Zoster","enrollment":105},{"nctId":"NCT06334861","phase":"","title":"Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-06-23","conditions":"Herpes Zoster","enrollment":178},{"nctId":"NCT06614816","phase":"PHASE3","title":"Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-02-10","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT06224270","phase":"PHASE4","title":"Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2024-10","conditions":"Inflammatory Bowel Diseases, IBD","enrollment":""},{"nctId":"NCT05871541","phase":"PHASE1","title":"A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine","status":"COMPLETED","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2023-05-26","conditions":"Herpes Zoster (HZ), Shingles, Infectious Disease","enrollment":75},{"nctId":"NCT06592456","phase":"PHASE3","title":"A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-07-21","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT04748939","phase":"PHASE4","title":"Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT","status":"NOT_YET_RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2025-01","conditions":"Herpes Zoster","enrollment":140},{"nctId":"NCT04047979","phase":"PHASE2","title":"Systems Biology of Zoster Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-14","conditions":"Zoster, Zoster Varicella, Shingles","enrollment":38},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT02735915","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-11","conditions":"Herpes Zoster","enrollment":70},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT03771157","phase":"EARLY_PHASE1","title":"Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-02-01","conditions":"Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)","enrollment":33},{"nctId":"NCT05015686","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-09-30","conditions":"Varicella","enrollment":2400},{"nctId":"NCT03993717","phase":"","title":"Solid Organ Transplant SHINGRIX","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-01-30","conditions":"Kidney Transplant; Complications","enrollment":2},{"nctId":"NCT04089930","phase":"","title":"Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2020-06-01","conditions":"Lupus Erythematosus","enrollment":68},{"nctId":"NCT05371080","phase":"PHASE3","title":"A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-08-10","conditions":"Herpes Zoster","enrollment":3038},{"nctId":"NCT05158777","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-02-13","conditions":"Varicella","enrollment":2480},{"nctId":"NCT04072497","phase":"PHASE1, PHASE2","title":"A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-20","conditions":"Herpes Zoster","enrollment":522},{"nctId":"NCT01911065","phase":"PHASE4","title":"T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Herpes Zoster","enrollment":54},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT04523246","phase":"EARLY_PHASE1","title":"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2020-09-01","conditions":"Herpes Zoster, Allergy and Immunology, Corona Virus Infection","enrollment":217},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT06088745","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine","status":"RECRUITING","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-09-28","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":4},{"nctId":"NCT03702231","phase":"PHASE2","title":"Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL)","enrollment":116},{"nctId":"NCT04384016","phase":"PHASE4","title":"Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2021-04-17","conditions":"Chickenpox","enrollment":201},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":"Influenza, Herpes Zoster","enrollment":148},{"nctId":"NCT05839301","phase":"PHASE3","title":"A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2023-04-27","conditions":"Varicella","enrollment":1200},{"nctId":"NCT05669625","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2022-12-26","conditions":"Varicella","enrollment":12440},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT05750017","phase":"PHASE1","title":"A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-03-23","conditions":"Herpes Zoster, Vaccine-Preventable Diseases","enrollment":66},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT05718037","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2023-08-01","conditions":"Herpes Zoster","enrollment":40},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05460429","phase":"PHASE4","title":"Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-30","conditions":"Varicella","enrollment":37920},{"nctId":"NCT05470855","phase":"PHASE4","title":"Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-06","conditions":"Varicella","enrollment":45400},{"nctId":"NCT05664152","phase":"NA","title":"An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years","status":"UNKNOWN","sponsor":"GC Biopharma Corp","startDate":"2023-02","conditions":"Varicella Zoster Virus Infection","enrollment":250},{"nctId":"NCT05245838","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2022-01-10","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":150},{"nctId":"NCT04516408","phase":"NA","title":"Recombinant Zoster Vaccine in Stable SLE Patients","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-04-20","conditions":"Herpes Zoster, Recombinant Zoster Vaccine, Systemic Lupus Erythematosus","enrollment":464},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":"Varicella","enrollment":450},{"nctId":"NCT01600079","phase":"","title":"ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-15","conditions":"Herpes Zoster, Shingles","enrollment":1505647},{"nctId":"NCT00940940","phase":"PHASE4","title":"Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2009-10","conditions":"Kidney Transplant","enrollment":4},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT03439657","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-12","conditions":"Herpes Zoster","enrollment":913},{"nctId":"NCT05150392","phase":"PHASE3","title":"An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2018-07-11","conditions":"Varicella","enrollment":1193},{"nctId":"NCT04334577","phase":"PHASE3","title":"Study on Efficacy of Attenuated Zoster Vaccine, Live","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2020-04-20","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT02538341","phase":"PHASE2","title":"Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2016-05","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis","enrollment":617},{"nctId":"NCT00851786","phase":"PHASE2","title":"Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-04-29","conditions":"Herpes Zoster, HIV Infections","enrollment":395},{"nctId":"NCT00001125","phase":"PHASE1","title":"Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Chickenpox","enrollment":60},{"nctId":"NCT00000837","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":77,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Herpes Zoster Vaccine, Live","genericName":"Herpes Zoster Vaccine, Live","companyName":"Changchun BCHT Biotechnology Co.","companyId":"changchun-bcht-biotechnology-co","modality":"Biologic","firstApprovalDate":"","aiSummary":"This live attenuated vaccine stimulates the immune system to recognize and respond to varicella-zoster virus, preventing herpes zoster (shingles) reactivation. Used for Prevention of herpes zoster (shingles) in adults with prior varicella infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}